Table 3. Univariate analysis for OS and LRF.
| Variable | HR (95% CI) | P value |
|---|---|---|
| OS | ||
| 4DCT | 0.81 (0.45–1.45) | 0.47 |
| kV | 0.55 (0.34–0.89) | 0.02 |
| RT dose | 1.0 (1.0–1.01) | 0.11 |
| ECOG score | 1.26 (0.86–1.86) | 0.24 |
| Female | 0.78 (0.49–1.25) | 0.30 |
| Tumor volume | 1.002 (1.001–1.003) | 0.0004 |
| Age | 1.01 (0.99–1.03) | 0.33 |
| Stage 3 | 0.98 (0.31–3.12) | 0.97 |
| Stage 4 | 1.37 (0.33–5.79) | 0.66 |
| PET scan | 1.34 (0.61–2.94) | 0.46 |
| Pre RT chemo | 0.70 (0.43–1.13) | 0.14 |
| Post RT chemo | 0.91 (0.54–1.55) | 0.74 |
| Mediastinoscopy | 0.65 (0.37–1.14) | 0.13 |
| Bronchoscopy | 0.85 (0.53–1.34) | 0.48 |
| Cisplatin/Etop | 0.92 (0.32–2.66) | 0.88 |
| Carbo/Taxol | 0.77 (0.31–1.95) | 0.58 |
| Taxol | 1.40 (0.37–5.29) | 0.62 |
| Adenocarcinoma | 0.35 (0.14–0.84) | 0.02 |
| SCC | 0.94 (0.39–2.27) | 0.89 |
| LRF | ||
| 4DCT | 0.74 (0.36–1.50) | 0.40 |
| kV | 0.56 (0.30–1.05) | 0.07 |
| RT dose | 1.001 (1.0–1.001) | 0.06 |
| ECOG | 1.15 (0.64–2.10) | 0.64 |
| Female | 0.92 (0.50–1.68) | 0.78 |
| Tumor volume | 1.001 (1.0–1.002) | 0.49 |
| Age | 0.98 (0.96–1.0) | 0.14 |
| Stage 3 | 0.85 (0.20–3.60) | 0.82 |
| Stage 4 | 0.73 (0.12–4.45) | 0.73 |
| PET | 0.98 (0.40–2.38) | 0.96 |
| Pre RT chemo | 0.68 (0.36–1.28) | 0.23 |
| Post RT chemo | 1.70 (0.90–3.20) | 0.10 |
| Mediastinoscopy | 0.36 (0.15–0.86) | 0.02 |
| Bronchoscopy | 1.02 (0.55–1.87) | 0.96 |
| Cisplatin/Etop | 1.01 (0.25–4.12) | 0.72 |
| Carbo/Taxol | 0.84 (0.26–2.78 | 0.78 |
| Taxol | 0.33 (0.03–3.24) | 0.34 |
| Adenocarcinoma | 0.19 (0.06–0.61) | 0.005 |
| SCC | 0.56 (0.18–1.70) | 0.30 |
OS, overall survival; LRF, locoregional failure; HR, hazard ratio; kV, kilovoltage; RT, radiation therapy; 4DCT, four dimensional computed tomography; ECOG PS, Eastern cooperative oncology group performance status; PET, positron emission tomography; Etop, etoposide; Carbo, Carboplatin; SCC, squamous cell carcinoma.